Back to homepage

Tag "hepatotoxicity"

Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL* protocol

Authors: Juan José Cerezo-Manchado, Olga Meca Birlanga, Luis García de Guadiana Romualdo, Ignacio Gil-Ortega, Antonio Martínez Francés, Teodoro Iturbe-Hernandez

This article discusses an update to the ANIBAL protocol in light of the COVID-19 pandemic.

More▸

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Authors: Teodoro Iturbe-Hernandez MD, Luis García de Guadiana Romualdo MD, Ignacio Gil Ortega MD, Antonio Martínez Francés MD, Olga Meca Birlanga MD, Juan José Cerezo-Manchado MD

In this review, the available information on the antithrombotic management of atrial fibrillation patients at discharge after COVID-19 infection is updated. In addition, a practical algorithm, considering renal and liver function, which facilitates the anticoagulation choice at discharge is presented.

More▸